Galazi Myria, Rodriguez-Vida Alejo, Ng Tony, Mason Malcolm, Chowdhury Simon
Department of Medical Oncology, Guy's Hospital, London, SE1 9RT, UK.
Expert Rev Anticancer Ther. 2014 Nov;14(11):1305-15. doi: 10.1586/14737140.2014.972948. Epub 2014 Oct 30.
Metastatic castration-resistant prostate cancer remains a lethal disease despite considerable progress in systemic therapy over the past decade. The recent advances in genomic sequencing have improved the molecular classification of prostate cancer. The translation of genomic data into clinically relevant prognostic and predictive biomarkers to guide therapy is still in its infancy and therapies for castration-resistant prostate cancer are still used empirically. We discuss these genomic aberrations in more detail, focusing on androgen receptor signaling, ETS transcription factor gene rearrangements and PTEN loss. The incorporation of this genomic data within early phase clinical trials is evolving and may prove significant in advancing personalized care in prostate cancer.
尽管在过去十年中全身治疗取得了显著进展，但转移性去势抵抗性前列腺癌仍然是一种致命疾病。基因组测序的最新进展改善了前列腺癌的分子分类。将基因组数据转化为临床相关的预后和预测生物标志物以指导治疗仍处于起步阶段，去势抵抗性前列腺癌的治疗仍在凭经验使用。我们将更详细地讨论这些基因组异常，重点关注雄激素受体信号传导、ETS转录因子基因重排和PTEN缺失。在早期临床试验中纳入这些基因组数据正在不断发展，可能会在推进前列腺癌的个性化治疗方面发挥重要作用。
